No Fanfare For US Approval Of Sanofi's GLP-1 Adlyxin

Sanofi has secured US approval for its a once-daily mealtime GLP-1 injection Adlyxin (lixisenatide) as an adjunct to diet and exercise for the treatment of adults with type 2 diabetes, but as the sixth GLP-1 product to enter this market the drug is unlikely to gain a strong foothold.